EMA Recommends Granting a Marketing Authorisation for Aumolertinib By Ogkologos - January 8, 2026 565 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with EGFR-mutated NSCLC Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Heartburn Medications Pulled From Shelves Because They May Cause Cancer January 13, 2020 Women Diagnosed with Early Breast Cancer Since 2000 Have About a... October 24, 2024 Phlebotomist Breaks Into Ballet Performance In The Middle Of The Hospital September 16, 2021 FDA Approves First Immunotherapy Treatment For Breast Cancer March 11, 2019 Load more HOT NEWS FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer No Difference in DFS Between Post-adjuvant Chemotherapy and Placebo In High-Risk... Breast Cancer Survivor Shares Inspiring Images Of Herself As “Bold Indian... 2020 round-up: Our biggest cancer stories of the year
